
-
India's Modi in Sri Lanka for defence and energy deals
-
'No one to return to': Afghans fear Pakistan deportation
-
Fractious Republicans seek unity over Trump tax cuts
-
America's passion for tariffs rarely pays off, economists warn
-
Trump's global tariff takes effect in dramatic US trade shift
-
North Korea's Kim fires new sniper rifle while visiting troops
-
Norris fastest in McLaren 1-2 as fires again disrupt Japan GP practice
-
Vital European defence startups still facing hurdles
-
'I don't have a voice in my head': Life with no inner monologue
-
Pakistan chasing 265 to win shortened third New Zealand ODI
-
US soybeans, energy: Who is hit by China's tariff retaliation?
-
Green, Sengun lift Rockets over Thunder, Celtics clinch record
-
Ariya downs defending champ Korda to advance at LPGA Match Play
-
Ovechkin ties Gretzky's all-time record of 894 NHL goals
-
Under-pressure Doohan vows to learn from Japanese GP smash
-
Harman goes four clear at Texas Open
-
McLaughlin-Levrone, Thomas cruise to wins at opening Grand Slam Track
-
US cardinal defrocked for sex abuse dies at 94
-
Lula admits 'still a lot to do' for Indigenous Brazilians
-
England, Germany and Spain on mark in women's Nations League
-
Judge orders return to US of Salvadoran man deported in error
-
Amadou of Malian blind music duo dies aged 70
-
Freeman hat-trick eases Northampton into Champions Cup quarters with Clermont win
-
Defiant Trump dismisses stock market's tariff plunge
-
Musiala injury sours Bayern win at Augsburg
-
Peruvian schoolkids living in fear of extortion gangs
-
Top seed Pegula rallies to oust defending champ Collins in Charleston
-
Amadou of Malian blind music duo Amadou & Mariam dies aged 70
-
California to defy Trump's tariffs to allay global trade fears
-
Bayern's Musiala subbed off with injury days out from Inter clash
-
Russian strike kills 16 in Ukraine leader's home city, children among dead
-
NBA fines Grizzlies' Morant for imaginary gun gesture
-
Trump tariffs offer opportunity for China
-
UK comedian Russell Brand charged with rape
-
Marsh, Markram help Lucknow edge Mumbai in IPL
-
Israel attorney general accuses PM of 'conflict of interest' in security chief dismissal
-
Emery glad to see Rashford make landmark appearance
-
Sean 'Diddy' Combs faces more charges ahead of criminal trial
-
Russian missile strike kills 14 in Ukraine leader's home city
-
Trump's tariff Big Bang puts global economy under threat
-
I Am Maximus backed for National as Mullins hot streak continues
-
2014 World Cup winner Hummels to retire at season's end
-
Intercommunal violence kills dozens in central Nigeria
-
Nigerian, S. African music saw 'extraordinary growth' in 2024: Spotify
-
Russell Brand: From Hollywood star to rape suspect
-
France soccer star Mbappe unveiled in London... in waxwork form
-
Trump goads China as global trade war escalates
-
Israel expands Gaza ground offensive, hits Hamas in Lebanon
-
TikTok faces new US deadline to ditch Chinese owner
-
US Fed Chair warns tariffs will likely raise inflation, cool growth
RBGPF | 100% | 69.02 | $ | |
NGG | -5.25% | 65.93 | $ | |
RELX | -6.81% | 48.16 | $ | |
GSK | -6.79% | 36.53 | $ | |
AZN | -7.98% | 68.46 | $ | |
SCS | -0.56% | 10.68 | $ | |
BCE | 0.22% | 22.71 | $ | |
BCC | 0.85% | 95.44 | $ | |
CMSD | 0.7% | 22.83 | $ | |
RIO | -6.88% | 54.67 | $ | |
CMSC | 0.13% | 22.29 | $ | |
JRI | -7.19% | 11.96 | $ | |
RYCEF | -18.79% | 8.25 | $ | |
BTI | -5.17% | 39.86 | $ | |
VOD | -10.24% | 8.5 | $ | |
BP | -10.43% | 28.38 | $ |

Pfizer sees Covid-19 drug sales topping $50 bn in 2022
Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.
Pfizer, whose vaccinee developed with German company BioNTech was the first approved to counter the deadly virus, sees slightly lower 2022 revenues for the vaccine compared with the just-finished year, but a big infusion of revenues from Paxlovid, the company's pill for Covid-19.
Chief Executive Albert Bourla described 2021 as a "watershed year" for Pfizer, adding that the company's efforts in the pandemic "have fundamentally changed our company forever."
Still, shares fell Tuesday following the results, which lagged estimates in terms of fourth-quarter revenues.
Besides vaccines, sales were mixed across Pfizer's other divisions. Revenues dipped for internal medicine and inflammation and immunology, but rose for oncology, hospitals and rare disease.
Analysts have also projected higher 2022 profits compared with the company's forecasts.
- Heavy interest in therapeutic -
Pfizer reported annual profits of $22 billion, more than double the 2020 level. Annual revenues nearly doubled to $81.3 billion, with $36.8 billion from the Covid-19 vaccine.
The company projected 2022 revenues of between $98 and $102 billion.
The results are the latest to show how the coronavirus has transformed Pfizer, which a year ago had projected just $15 billion in Covid-19 vaccines sales in 2021 and ended up selling more than twice that amount after repeatedly lifting the forecast.
For 2022, Pfizer expects $32 billion in revenue from Covid-19 vaccines and $22 billion in revenues from Paxlovid.
Bourla said the company is currently working on a new vaccine candidate based on the Omicron variant of Covid-19, as well as a new "potential next-generation oral Covid-19 treatment."
The company expects to produce 120 million treatment courses for Paxlovid, with six million in the first quarter and 30 million the first half of 2022.
Pfizer executives described heavy interest in Paxlovid, with ongoing contract talks with about 100 governments around the world. The treatment has so far been approved in about 40 countries.
Bourla said the sales for Paxlovid "could be way bigger" than current forecasts. The 2022 estimate of $22 billion is based on signed contracts and negotiations where there is essentially an agreement, he said.
However, Chief Financial Officer Frank D'Amelio cautioned that there was "less potential upside" to 2022 estimates for Covid-19 vaccine revenues, compared with 2021 "when the vaccine was newly available and few people had received any doses of the vaccine."
Pfizer's scientists "continue to monitor the Covid-19 virus and believe it is unlikely that it will be fully eradicated in the foreseeable future," Bourla said.
"That said, we now have the tools -- in the forms of vaccines and treatments -- that we believe will help enable us to not only better manage the pandemic but also help countries move into the endemic phase," Bourla said.
"In other words, we believe these tools will help allow us to go back to normality and spend time with family and friends, travel, attend indoor dining and concerts, and enjoy many other activities while lowering the risk of overburdening hospitals and healthcare systems around the world."
Shares fell 2.8 percent to $51.75 in midday trading.
H.Silva--PC